Reduction of Decoy Receptor 3 Enhances TRAIL-Mediated Apoptosis in Pancreatic Cancer

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Wang, Wei ^b   Zhang, Mei ^a   Sun, Weimin ^a,c   Yang, Shanmin ^a   Su, Ying ^b   Zhang, Hengshan ^b   Liu, Chaomei ^a   Li, Xinfeng ^b   Lin, Ling ^b   Kim, Sunghee ^d   Okunieff, Paul ^a   Zhang, Zhenhuan ^a   Zhang, Lurong ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b FUJIAN MEDICAL UNIVERSITY   (China)

^c Second Military Medical College   (China)

^d BioPowerTech   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECOY RECEPTOR 3; GEMCITABINE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; PANCREATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; RNA INTERFERENCE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR BURDEN; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84886432544     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074272     Document Type: Article

References (39)

1. Stauffer SR, (2007) Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737. Curr Top Med Chem 7: 961-965.
2. Catz SD, Johnson JL, (2003) BCL-2 in prostate cancer: a minireview. Apoptosis 8: 29-37.
3. Flaherty KT, Stevenson JP, O'Dwyer PJ, (2001) Antisense therapeutics: lessons from early clinical trials. Curr Opin Oncol 13: 499-505.
4. Tsujimoto Y, (1998) Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes Cells 3: 697-707.
5. Bratton SB, Cohen GM, (2001) Apoptotic death sensor: an organelle's alter ego? Trends Pharmacol Sci 22: 306-315.
6. Karikari CA, Roy I, Tryggestad E, Feldmann G, Pinilla C, et al. (2007) Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol Cancer Ther 6: 957-966.
7. Cosman D, (1994) A family of ligands for the TNF receptor superfamily. Stem Cells 12: 440-455.
8. Ashkenazi A, Dixit VM, (1999) Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11: 255-260.
9. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, et al. (1999) Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 17: 331-367.
10. She QB, Bode AM, Ma WY, Chen NY, Dong Z, (2001) Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res 61: 1604-1610.
11. Farrelly N, Lee YJ, Oliver J, Dive C, Streuli CH, (1999) Extracellular matrix regulates apoptosis in mammary epithelium through a control on insulin signaling. J Cell Biol 144: 1337-1348.
12. Ibrahim SM, Ringel J, Schmidt C, Ringel B, Muller P, et al. (2001) Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 23: 72-79.
13. Zhan C, Patskovsky Y, Yan Q, Li Z, Ramagopal U, et al. (2011) Decoy strategies: the structure of TL1A:DcR3 complex. Structure 19: 162-171.
14. Connolly K, Cho YH, Duan R, Fikes J, Gregorio T, et al. (2001) In vivo inhibition of Fas ligand-mediated killing by TR6, a Fas ligand decoy receptor. J Pharmacol Exp Ther 298: 25-33.
15. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, et al. (2002) TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16: 479-492.
16. Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, et al. (1999) A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 274: 13733-13736.
17. Zhang J, Salcedo TW, Wan X, Ullrich S, Hu B, et al. (2001) Modulation of T-cell responses to alloantigens by TR6/DcR3. J Clin Invest 107: 1459-1468.
18. Shi G, Mao J, Yu G, Zhang J, Wu J, (2005) Tumor vaccine based on cell surface expression of DcR3/TR6. J Immunol 174: 4727-4735.
19. Shrader M, Pino MS, Lashinger L, Bar-Eli M, Adam L, et al. (2007) Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res 67: 1430-1435.
20. Xu ZW, Kleeff J, Friess H, Buchler MW, Solioz M, (2003) Synergistic cytotoxic effect of TRAIL and gemcitabine in pancreatic cancer cells. Anticancer Res 23: 251-258.
21. Chen J, Zhang L, Kim S, (2004) Quantification and detection of DcR3, a decoy receptor in TNFR family. J Immunol Methods 285: 63-70.
22. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, et al. (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396: 699-703.
23. Mori T, Doi R, Toyoda E, Koizumi M, Ito D, et al. (2005) Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer. Surgery 138: 71-77.
24. Song JJ, An JY, Kwon YT, Lee YJ, (2007) Evidence for two modes of development of acquired tumor necrosis factor-related apoptosis-inducing ligand resistance. Involvement of Bcl-xL. J Biol Chem 282: 319-328.
25. American Cancer Society (2013) Pancreatic Cancer Overview. Available: http://www.cancer.org/acs/groups/cid/documents/webcontent/003071-pdf.pdf. Accessed 14 May 2013.
26. Hylander BL, Pitoniak R, Penetrante RB, Gibbs JF, Oktay D, et al. (2005) The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 3: 22.
27. Jacob D, Davis JJ, Zhang L, Zhu H, Teraishi F, et al. (2005) Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter. Cancer Gene Ther 12: 109-115.
28. Hall MA, Cleveland JL, (2007) Clearing the TRAIL for Cancer Therapy. Cancer Cell 12: 4-6.
29. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, et al. (1997) The receptor for the cytotoxic ligand TRAIL. Science 276: 111-113.
30. Pan G, Ni J, Wei YF, Yu G, Gentz R, et al. (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277: 815-818.
31. Boehrer S, Nowak D, Hoelzer D, Mitrou PS, Chow KU, (2006) The molecular biology of TRAIL-mediated signaling and its potential therapeutic exploitation in hematopoietic malignancies. Curr Med Chem 13: 2091-2100.
32. Mori T, Doi R, Kida A, Nagai K, Kami K, et al. (2007) Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells. J Surg Res 142: 281-286.
33. Okamoto K, Ocker M, Neureiter D, Dietze O, Zopf S, et al. (2007) bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells. J Cell Mol Med 11: 349-361.
34. Finnberg N, El-Deiry WS, (2006) Selective TRAIL-induced apoptosis in dysplastic neoplasia of the colon may lead to new neoadjuvant or adjuvant therapies. Clin Cancer Res 12: 4132-4136.
35. Tsuji S, Hosotani R, Yonehara S, Masui T, Tulachan SS, et al. (2003) Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma. Int J Cancer 106: 17-25.
36. Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, et al. (2000) Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci U S A 97: 1230-1235.
37. Li H, Zhang L, Lou H, Ding I, Kim S, et al. (2005) Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus. Am J Clin Pathol 124: 282-287.
38. Chang YC, Chen TC, Lee CT, Yang CY, Wang HW, et al. (2008) Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Blood 111: 5054-5063.
39. Chen PH, Yang CR, (2008) Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-, Akt-, and NF-kappa B-dependent pathway. J Immunol 181: 8441-8449.